Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU.

Although the cumulative incidence of CNS recurrence was numerically lower with neratinib than with placebo both at 2 and 5 years, the between-group difference did not reach statistical significance (Table 2 ) [ 16 , 17 ].

also in 111,027 other papers